Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinic

    1. Timothy J Mitchison2
    1. 1Department of Physics and Department of Biology, Center for Quantitative Systems Biology, Hong Kong Baptist University, Hong Kong, China
    2. 2Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA
    1. Correspondence should be addressed to J Shi; Email: jshi{at}hkbu.edu.hk


    Anti-mitotic cancer drugs include classic microtubule-targeting drugs, such as taxanes and vinca alkaloids, and the newer spindle-targeting drugs, such as inhibitors of the motor protein; Kinesin-5 (aka KSP, Eg5, KIF11); and Aurora-A, Aurora-B and Polo-like kinases. Microtubule-targeting drugs are among the first line of chemotherapies for a wide spectrum of cancers, but patient responses vary greatly. We still lack understanding of how these drugs achieve a favorable therapeutic index, and why individual patient responses vary. Spindle-targeting drugs have so far shown disappointing results in the clinic, but it is possible that certain patients could benefit if we understand their mechanism of action better. Pre-clinical data from both cell culture and mouse tumor models showed that the cell death response is the most variable point of the drug action. Hence, in this review we focus on current mechanistic understanding of the cell death response to anti-mitotics. We first draw on extensive results from cell culture studies, and then cross-examine them with the more limited data from animal tumor models and the clinic. We end by discussing how cell type variation in cell death response might be harnessed to improve anti-mitotic chemotherapy by better patient stratification, new drug combinations and identification of novel targets for drug development.

    • Received 22 February 2017
    • Accepted 1 March 2017
    • Made available online as an Accepted Preprint 1 March 2017
    | Table of Contents